Onconetix Inc ONCO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
SRX Global Provides Shareholders with Update on Liquidation of Two Portfolio Investments and Adds an Investment in Onconetix (Nasdaq: ONCO)
-
CORRECTED: Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition
-
Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition
-
Onconetix Acquisition Target Realbotix Launches Pilot with Leading European Telecommunications Company to Deploy Humanoid Robots in Live Presentations and Events
-
Onconetix Acquisition Target Realbotix Secures Agreement for Humanoid Robot Appearance on Emmy Award-Winning Streaming Series
-
Onconetix Announces Appointment of Ralph Schiess, PhD to Board of Directors of Proteomedix AG
Trading Information
- Previous Close Price
- $0.55
- Day Range
- $0.46–0.53
- 52-Week Range
- $0.46–200.00
- Bid/Ask
- $0.52 / $0.52
- Shares Outstanding
- 5.24M
- Market Cap
- $2.51M
- Volume/Avg
- 637,366 / 3M
Key Statistics
- Price/Earnings (Normalized)
- 0.00
- Price/Sales
- 0.02
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 2
- Website
- https://www.onconetix.com
Valuation
|
Metric
|
ONCO
|
|---|---|
Price/Earnings (Normalized) | 0.00 |
Price/Book Value | 0.16 |
Price/Sales | 0.02 |
Price/Cash Flow | — |
Price/Earnings
ONCO
Financial Strength
|
Metric
|
ONCO
|
|---|---|
Quick Ratio | 2.04 |
Current Ratio | 2.21 |
Interest Coverage | −31.79 |
Quick Ratio
ONCO
Profitability
|
Metric
|
ONCO
|
|---|---|
Return on Assets (Normalized) | −60.97% |
Return on Equity (Normalized) | −115.22% |
Return on Invested Capital (Normalized) | −94.38% |
Return on Assets
ONCO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|cvFDmGb | LOCK|#&Yb | $127B | |||
| Moderna Inc
MRNA
| LOCK|#hZgQ$ | LOCK|#$& | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|#@P>%k | LOCK|l>v@ | $81B | |||
| argenx SE ADR
ARGX
| LOCK|>zz&^q | LOCK|yc | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|b^%$?T | LOCK|$B | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|T&#w<?D | LOCK|LjFc | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|G%^!@hs | LOCK|>?nt | $27B | |||
| Incyte Corp
INCY
| LOCK|BDkbF&V | LOCK|D$& | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|$Jx%<@ | LOCK|#p | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|&&?y^&p | LOCK|cb | $14B |
United States